NCT07293793

Brief Summary

This research presents a comprehensive consensus on pregnancy skin care, synthesizing expert recommendations to ensure maternal skin health while prioritizing fetal safety. It outlines safe and effective skin care practices tailored to the physiological and hormonal changes during pregnancy. Key guidelines emphasize the use of gentle cleansing, adequate hydration, mineral-based sun protection, and the selection of dermatologically safe ingredients such as vitamin C, hyaluronic acid, niacinamide, and azelaic acid. The consensus highlights the avoidance of potentially harmful substances including retinoids, high-dose salicylic acid, and certain chemical sunscreens. Additionally, the research provides clinical guidance on managing common pregnancy-related skin conditions and cautions against aggressive cosmetic procedures. The outcomes serve as a critical resource for dermatologists and healthcare providers to optimize skin care regimens during pregnancy, balancing efficacy with safety for both mother and child.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
7mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress39%
Dec 2025Dec 2026

First Submitted

Initial submission to the registry

December 6, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 19, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

December 25, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

8 months

First QC Date

December 6, 2025

Last Update Submit

December 6, 2025

Conditions

Keywords

ConsensusRecommendationsSkin CarePregnancy

Outcome Measures

Primary Outcomes (1)

  • Achievement of Expert Consensus on Pregnancy-Safe Skin Care Recommendations

    The primary outcome of this Delphi study was to establish consensus-based, evidence-aligned recommendations for safe skin care practices, cosmetic ingredients, and dermatologic treatments during pregnancy. Consensus was defined a priori as: ≥75% of experts scoring a statement 7-9 on a 9-point Likert scale (agreement), with a median score ≥7. This outcome reflects the degree to which experts converged on the safety categories, usage guidelines, and clinical management strategies for skin care in pregnant patients.

    6-12 weeks

Secondary Outcomes (1)

  • Classification of Dermatologic Ingredients and Procedures According to Safety Profile

    6-12 weeks

Study Arms (1)

Expert Panel

A cohort of dermatology and aesthetic medicine experts from the MENA region participating in a Modified Delphi process to develop consensus recommendations on Skin Care dermo cosmetics in Pregnancy

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

e study population consisted of a multidisciplinary panel of experts selected to represent diverse clinical, academic, and regional perspectives relevant to dermatologic care during pregnancy to ensure comprehensive evaluation of skin care ingredient safety, therapeutic practices, and procedure-related considerations for pregnant women.

You may qualify if:

  • Board-certified dermatologist or plastic surgeon OR physician practicing aesthetic medicine.
  • Minimum of 5 years of clinical experience.
  • Practicing within Egypt or the Middle East and North Africa (MENA) region.
  • Willingness to participate in Delphi rounds and provide expert ratings.
  • Ability to read and respond to surveys in English.

You may not qualify if:

  • Inability or unwillingness to complete Delphi rounds.
  • Lack of clinical experience with Pregnant ladies.
  • Industry representatives without direct clinical practice.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Venus Research Center

Cairo, Egypt

Location

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2025

First Posted

December 19, 2025

Study Start

December 25, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

December 19, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Delphi studies do not collect patient data, medical records, biological samples, or identifiable clinical information. Experts only give opinions, not "IPD." Their responses are anonymized, and sharing identifiable expert-level responses is not required and often discouraged

Locations